Glenmark Pharma receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets, 1 mg/20 mcg

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets, 1 mg/20 mcg, the generic version of Minastrin®1 24 Fe Tablets, of Allergan Pharmaceuticals International Limited.

According to IQVIATM sales data for the 12 month period ending October 2017, the Minastrin®1 24 Fe Tablets market2 achieved annual sales of approximately $337.0 million*.

Glenmark's current portfolio consists of 130 products authorized for distribution in the U.S. marketplace and 58 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.592.85 as compared to the previous close of Rs. 584.2. The total number of shares traded during the day was 173168 in over 3887 trades.

The stock hit an intraday high of Rs. 598.1 and intraday low of 581.75. The net turnover during the day was Rs. 102415025..

1All brand names and trademarks are the property of their respective owners

2Market includes brand and all available therapeutic equivalents

*IQVIATM National Sales Perspectives: Retail & Non-Retail, October 2017

Source : Equity Bulls

Keywords